Intercept pharmaceuticals, inc. (ICPT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities:
Net loss

-347,394

-344,681

-334,528

-314,149

-317,922

-309,242

-332,509

-340,656

-352,027

-360,367

-369,136

-385,351

-376,086

-412,830

-381,043

-343,122

-313,717

-226,429

-172,999

-157,947

-76,583

-283,226

-260,769

-256,663

-303,610

-67,792

-86,114

-59,564

-51,173

-43,643

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Foreign currency loss on liquidation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-191

-191

0

0

0

Revaluation of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

170,832

169,262

190,018

251,385

28,441

54,198

34,859

28,986

24,625

0

0

0

Stock-based compensation

53,558

55,982

54,308

53,172

52,506

49,914

53,799

55,042

55,212

56,968

60,748

60,055

50,022

46,205

39,192

32,317

34,695

34,189

25,701

25,266

22,429

20,127

19,431

17,178

15,274

9,446

8,575

6,085

4,564

3,348

0

0

0

(Accretion) amortization of (discount) premium on investment debt securities

-533

302

894

1,136

834

33

-6,472

-5,888

-4,953

-3,429

-5,898

-5,677

-5,460

-4,939

5,521

6,371

6,961

6,302

5,492

4,591

3,698

3,366

2,929

2,456

2,166

1,615

1,194

646

118

118

0

0

0

Amortization of deferred financing costs

2,338

2,130

1,927

1,746

1,575

1,542

1,509

1,477

1,447

1,417

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from sale of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Depreciation

3,468

3,700

3,888

6,782

4,306

4,600

4,895

5,154

5,088

4,600

4,900

4,161

3,949

3,831

2,819

2,589

2,125

1,691

1,292

959

631

443

236

183

145

106

0

0

0

-

-

0

0

Non-cash operating lease cost

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on lease termination

-

1,995

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on the disposal of fixed assets

-

-2,682

-2,682

-2,682

-3,113

-1,331

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of bonds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Accretion of debt discount

23,770

21,189

18,670

15,877

14,327

14,031

13,740

13,456

13,177

12,904

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for allowance of credit losses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets:
Accounts receivable

15,153

12,350

10,742

16,851

12,496

9,193

7,593

6,279

6,319

7,375

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

13,227

5,353

6,146

4,419

-990

3,682

3,467

4,868

4,461

7,535

-344

-8,114

-4,378

-4,284

7,773

13,436

11,058

7,516

-171

1,192

4,852

3,371

6,063

7,569

3,965

1,714

-803

-393

-31

387

0

0

0

Inventory

3,469

1,354

1,873

1,873

-568

3,628

3,578

3,131

5,822

1,201

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Security deposits

-1,729

-2,562

-1,033

-534

379

-7,153

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

24,665

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating liabilities:
Accounts payable, accrued expenses and other current liabilities

49,312

56,411

56,041

40,100

30,222

10,332

988

6,346

11,164

29,226

34,780

30,567

20,453

19,960

16,975

20,773

26,185

32,218

15,687

11,868

7,607

6,200

9,635

6,467

5,538

3,514

989

94

1,732

2,241

0

0

0

Operating lease liabilities

-6,819

-6,767

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest payable

1,712

562

0

0

0

-

-

-

-1

208

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Deferred revenue

-

-2,432

-1,622

-1,622

-527

-2,022

-2,062

-7,155

-6,379

-5,693

-3,935

591

2,455

2,129

371

899

-1,782

-1,782

-1,781

-1,781

-780

-741

-701

-662

-1,621

-1,622

-1,621

-1,739

-2,092

-2,446

0

0

0

Litigation settlement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long-term other liabilities

-

12,717

9,009

10,051

11,232

-1,807

-1,790

-1,827

-1,097

5,578

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) operating activities

-251,919

-236,613

-228,941

-233,766

-235,273

-240,714

-264,361

-268,918

-276,768

-265,402

-278,405

-334,369

-350,084

-342,441

-318,667

-240,184

-203,165

-162,902

-129,357

-119,604

-105,013

-87,738

-66,019

-48,591

-34,688

-28,006

-21,873

-19,125

-17,491

-15,749

0

0

0

Cash flows from investing activities:
Purchases of investment debt securities

632,246

603,014

618,543

593,436

412,817

436,071

482,366

444,946

238,327

231,107

195,200

556,901

497,449

511,521

524,104

151,973

553,813

640,709

568,295

567,046

310,834

204,344

235,570

227,394

131,305

125,825

152,172

125,723

76,184

65,940

0

0

0

Sales and maturities of investment debt securities

421,443

415,162

401,759

391,702

393,307

388,168

424,038

470,402

499,262

529,274

493,989

451,261

458,744

456,465

467,138

402,871

336,558

257,172

193,410

171,532

132,292

112,402

100,849

80,531

78,970

57,241

27,555

15,116

3,119

1,119

0

0

0

Redemptions of certificates of deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7

-3

0

0

0

Purchases of equipment, leasehold improvements, and furniture and fixtures

835

1,136

1,163

1,146

811

167

335

2,199

6,456

10,392

11,176

9,130

6,697

5,079

4,526

5,945

6,412

5,935

6,367

8,198

6,273

4,643

5,197

2,211

1,920

1,629

135

59

27

38

0

0

0

Net cash provided by investing activities

-211,638

-188,988

-217,947

-202,880

-20,321

-48,070

-59,604

22,287

254,479

287,775

288,554

-68,800

-45,402

-60,135

-61,492

199,953

-223,667

-389,472

-381,252

-403,712

-184,815

-96,585

-139,919

-149,075

-54,255

-70,214

-124,869

-110,779

-73,085

-64,857

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

558,756

0

0

0

-

-

-

-

61,169

139,955

169,879

108,499

108,499

0

0

0

Proceeds from issuance of common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Costs associated with issuance of stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Payments of capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

23

81

0

0

0

Proceeds from exercise of options, net

8,619

8,993

3,673

5,615

4,825

4,363

3,962

1,677

2,763

2,838

2,821

3,914

4,243

5,173

5,547

5,083

5,210

6,713

6,665

7,578

7,698

7,508

7,031

7,149

7,605

4,894

0

0

0

-

0

0

0

Payments of employee withholding taxes related to stock-based awards

2,689

2,158

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

0

0

0

-

0

0

0

Proceeds from issuance of convertible promissory notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Net cash (used in) provided by financing activities

456,614

457,519

452,079

452,449

263,216

263,545

263,866

263,034

2,763

2,838

2,679

413,123

413,452

414,382

414,898

4,909

372,332

565,469

565,421

566,437

383,146

190,983

190,507

190,485

68,444

66,072

144,263

172,098

108,564

108,418

0

0

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-1,362

-386

-1,196

-22

-1,769

-1,526

-763

-714

1,447

1,127

2,200

376

-221

-873

-1,880

-1,234

-661

-376

0

0

0

-

-

-

-

-

-

-

-19

-7

0

0

0

Net (decrease) increase in cash, cash equivalents and restricted cash

-8,305

31,532

3,995

15,781

5,853

-26,765

-60,862

15,689

-18,079

26,338

15,028

10,330

17,745

10,933

32,859

-36,556

-55,161

12,719

54,298

43,296

93,155

6,660

-15,432

-7,179

-20,499

-32,148

-2,479

42,193

17,966

27,804

0

0

0

Supplemental disclosures of noncash activities:
Conversion of promissory note payable, including accrued interest of $91,250 into common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Issuance of 108,169 warrants for private placement agent fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Acquisition of equipment pursuant to capital leases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Issuance of common stock for cashless warrant exchange

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,646

1,018

0

0

0

Supplemental disclosure of cash flow information:
Cash paid during the year for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,931

-3

4

0

0

0